Pinealon (Glu-Asp-Arg; EDR) is a synthetic tripeptide. A laboratory study reported cellular effects under oxidative-stress conditions; it does not establish clinical benefit.

Insufficient evidence. Review the research and limitations before relying on this record.

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the same Khavinson short-peptide programme that produced Epitalon, proposed to act as a tissue-specific "bioregulator" of gene expression in brain tissue. Laboratory work from that group reports increased cell viability through suppression of free-radical levels and activation of proliferative processes. No receptor or defined molecular target has been identified, and the bioregulator concept itself has not been validated outside the originating group.

No pharmacokinetic data exists in any species or by any route.

No controlled human trial has been published. What exists is laboratory work reporting cellular effects under oxidative stress, which does not establish a clinical benefit. The supporting literature is overwhelmingly Russian-language, older, and produced by institutions connected to the original developers, so the corrective function of independent replication has not been applied.

No human safety dataset exists. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.

The cited study is cellular/preclinical. No robust formulation-specific clinical efficacy, safety, interaction, half-life, protocol, or dosing conclusion is available in Peppy.